期刊文献+

他汀类药物在脑卒中一级和二级预防中的地位

下载PDF
导出
摘要 他汀类药物已成为心血管病特别是冠心病的主要用药。然而,在脑卒中防治中,他汀类药物的使用一直没能受到足够的重视,直至2006年新英格兰医学杂志发表的强化降脂治疗预防脑卒中再发试验结果才使我们真正意识到在脑卒中患者中使用他汀类药物的重要性。基于SPARCL研究证据,2008年2008AHA/ASA指南强调:对于动脉粥样硬化性脑卒中或短暂性脑缺血发作患者,即使无冠心病病史,也推荐强化降脂治疗,以降低脑卒中和心血管事件风险。新指南进一步扩大了他汀强化干预的人群范围。
作者 邹阳春
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2009年第4期331-333,共3页 Chinese Journal of Arteriosclerosis
  • 相关文献

参考文献26

  • 1王薇,赵冬,刘静,孙佳艺,吴桂贤,曾哲淳,刘军,秦兰萍,吴兆苏.中国35~64岁人群血压水平与10年心血管病发病危险的前瞻性研究[J].中华内科杂志,2004,43(10):730-734. 被引量:147
  • 2赵水平,吴军,谭利明,胡治平,肖志杰,聂赛,周宏年,蒋波.他汀类药物对急性脑梗死的抗炎作用[J].中华医学杂志,2005,85(40):2841-2845. 被引量:48
  • 3Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region [ J ]. lnt J Epidemiol, 2003, 32 : 563.
  • 4Polark JF, Shemanski L, OLeary DH, et al. Hypoechoic plaque at US of the carotid artery : an independent risk factor for incident stroke in adults aged 65 years or older [J]. Radiology, 1998, 208: 649-654.
  • 5Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke : the Atherosclerosis Risk in Communities (ARIC) Study [ J]. Stroke, 2003, 34: 623.
  • 6Napoli D, Papa F. Inflammation, statins, and outcome after ischemic stroke [ J]. Stroke, 2001,32:2 446--447.
  • 7Blauw Gj, Lagaay AM, Smelt AH, et al. Stroke, statins, and cholesterol : a meta - analysis of randomized, placebo - controlled, double - blind trials with HMG-CoA reduetase inhibitors [J]. Stroke, 1997, 28: 946- 950.
  • 8Byington RP, Davis BR, Plehn JF. Reduction of stroke events with pravastatin: the PPP project [ J ]. Circulation, 2001,103 : 387-392.
  • 9PPP project Investigators. Design, rationale, and baseline characteristics of the prospective pravastatin pooling project [ J ]. Am J Cardiol, 1995, 76: 899-905.
  • 10The SPARCL Investigators. Design and baseline characteristics of the Stroke Preventionby Aggressive Reduction in Cholesterol Levels (SPARCL) Study [J]. Cerebrovasc Dis, 2003, 16: 389.

二级参考文献71

  • 1周冀英,董为伟.脑梗死患者循环白细胞对内皮细胞金属蛋白酶9表达的影响[J].中华医学杂志,2004,84(12):979-981. 被引量:15
  • 2World Health Organization . Multination monitoring of treads and determinants in cardiovascular disease (MONICA project) and manual of operation. Geneva: Cardiovascular Disease Unit ,1993.
  • 3Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).JAMA, 1993,269:3015-3023.
  • 4Wilson PW, D′Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories.Circulation,1998,97:1837-1847.
  • 5Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002,360:1903-1913.
  • 6Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med, 2001,345:1291-1297.
  • 7Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA,2003,289:2560-2572.
  • 8Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation,1998,97:1876-1887.
  • 9Kim JS, Yoon SS, Kim YH, et al. Serial measurement of interleukin-6,transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke,1996, 27: 1553-1557.
  • 10Vila N, Castillo J, Davalos A, et al. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke,2000, 31: 2325-2329.

共引文献320

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部